Hyphens Pharma International Future Growth
Future criteria checks 1/6
Hyphens Pharma International is forecast to grow earnings and revenue by 7.5% and 2.3% per annum respectively. EPS is expected to grow by 7.6% per annum. Return on equity is forecast to be 15.3% in 3 years.
Key information
7.5%
Earnings growth rate
7.6%
EPS growth rate
Pharmaceuticals earnings growth | 16.5% |
Revenue growth rate | 2.3% |
Future return on equity | 15.3% |
Analyst coverage | Low |
Last updated | 15 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 196 | 12 | 10 | N/A | 1 |
12/31/2025 | 192 | 12 | 9 | N/A | 2 |
12/31/2024 | 183 | 11 | 9 | N/A | 2 |
3/31/2024 | 185 | 10 | N/A | N/A | N/A |
12/31/2023 | 171 | 9 | 4 | 6 | N/A |
9/30/2023 | 156 | 7 | N/A | N/A | N/A |
6/30/2023 | 156 | 9 | 9 | 11 | N/A |
3/31/2023 | 156 | 10 | N/A | N/A | N/A |
12/31/2022 | 162 | 11 | 16 | 17 | N/A |
9/30/2022 | 156 | 12 | N/A | N/A | N/A |
6/30/2022 | 143 | 9 | 7 | 8 | N/A |
3/31/2022 | 132 | 8 | N/A | N/A | N/A |
12/31/2021 | 126 | 7 | 5 | 6 | N/A |
9/30/2021 | 126 | 6 | N/A | N/A | N/A |
6/30/2021 | 123 | 6 | 6 | 7 | N/A |
3/31/2021 | 126 | 6 | N/A | N/A | N/A |
12/31/2020 | 121 | 6 | 3 | 4 | N/A |
9/30/2020 | 126 | 7 | 3 | 4 | N/A |
6/30/2020 | 125 | 8 | 6 | 7 | N/A |
3/31/2020 | 124 | 7 | 8 | 9 | N/A |
12/31/2019 | 119 | 7 | 9 | 9 | N/A |
9/30/2019 | 117 | 6 | 8 | 10 | N/A |
6/30/2019 | 115 | 5 | 9 | 12 | N/A |
3/31/2019 | 117 | 5 | 8 | 11 | N/A |
12/31/2018 | 121 | 5 | 4 | 8 | N/A |
9/30/2018 | 117 | 5 | 0 | 2 | N/A |
6/30/2018 | 117 | 6 | 4 | 5 | N/A |
3/31/2018 | 115 | 6 | 2 | 3 | N/A |
12/31/2017 | 113 | 6 | N/A | 5 | N/A |
12/31/2016 | 101 | 5 | N/A | 6 | N/A |
12/31/2015 | 78 | 5 | N/A | 6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1J5's forecast earnings growth (7.5% per year) is above the savings rate (2.1%).
Earnings vs Market: 1J5's earnings (7.5% per year) are forecast to grow slower than the SG market (9.1% per year).
High Growth Earnings: 1J5's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1J5's revenue (2.3% per year) is forecast to grow slower than the SG market (3.7% per year).
High Growth Revenue: 1J5's revenue (2.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1J5's Return on Equity is forecast to be low in 3 years time (15.3%).